ClinicalTrials.gg
RecruitingNCT07661056Updated Nov 12, 2026

Study to Determine if BHV-1300 is Effective and Safe in Adults With Graves' Disease

A Phase 3 interventional study of BHV-1300 and Placebo in Graves Disease, sponsored by Biohaven Therapeutics Ltd.. Recruiting at 63 sites in 3 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Biohaven Therapeutics Ltd. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2026; still recruiting 4 months later.
Updated Nov 12, 2026First site in Canada13 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 43 studies in Graves Disease with a site in United States — 16 open to participants now, 18 under way, 3 of them phase 3. Graves Disease · United States.

Planned enrollment
2nd of 33
300 · median 76
Started
2026
with 9 others
Phase 3
8 of 43
3 open now
Primary completion
2028-01
later than 10 of 17 live
Registered
39th of 43
by date
Lead sponsor
2 of 43
Biohaven Therapeutics Ltd.

Among the 43 studies in Graves Disease with a site in United States, this one is the 2nd largest by planned enrollment of the 33 interventional ones that give a count, is one of 10 that started in 2026, is one of 8 in phase 3, reaches primary completion later than 10 of the 17 other live ones, and was the 39th registered.

Graves Disease

162 studies on the registry are indexed under Graves Disease; 53 are open to participants now.

Browse Graves Disease studies →

Open to participants now

16 of the 43 studies in Graves Disease with a site in United States are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 39 Graves Disease studies recruiting now, 17 (44%) set no upper age limit and 20 (51%) stop at 75 or younger; 3 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Graves Disease with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of BHV-1300 in adult participants with Graves' disease who are actively hyperthyroid

03

Conditions studied

  • Graves Disease

Keywords

  • Hyperthyroidism
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Participants must have serologically confirmed Graves' disease as documented by presence of elevated autoantibodies
  2. Participants must have active hyperthyroidism due to Graves' disease

Key Exclusion Criteria:

  1. History of hyperthyroidism not caused by Graves' Disease (e.g., toxic adenoma or toxic multinodular goiter)
  2. History of treatment with radioactive iodine or thyroid surgery.
  3. Have received levothyroxine, desiccated thyroid extract, or T3 at any dose within six weeks of the Baseline/Day 1 Visit.
  4. Thyroid storm, i.e. severe thyrotoxicosis with evidence of systemic decompensation (e.g., Burch-Wartkofsky Point Scale of ≥ 45 or Japanese Thyroid Association category 1 or 2, with accompanying manifestations including hyperpyrexia, tachycardia, arrhythmias, congestive heart failure, agitation, delirium, psychosis, stupor, and coma, as well as nausea, vomiting, diarrhea, or hepatic failure) within 6 weeks of Screening.
  5. Have disease other than Graves' disease requiring treatment
  6. Have moderate to severe thyroid eye disease (TED) or are expected to require immediate surgical intervention and/or are planning corrective surgery/irradiation or medical therapy for TED during study participation.
  7. Are expected to require urgent or emergent thyroid surgery or ablation within six weeks of Baseline/Day 1 or throughout the study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    BHV-1300

    BHV-1300 is delivered subcutaneously via autoinjector. Participants will be randomized in a 2:1 ratio to receive either BHV-1300 or placebo.

    Drug: BHV-1300

  • Placebo comparator
    Placebo

    Matching placebo is delivered subcutaneously via autoinjector. Participants will be randomized in a 2:1 ratio to receive either BHV-1300 or placebo.

    Drug: Placebo

Interventions

  • delivered subcutaneously via autoinjector

  • DrugPlacebo

    delivered subcutaneously via autoinjector

06

What researchers measure

Primary outcomes

  1. Number of participants on BHV-1300 vs placebo who are not on an antithyroid drug and with normal thyroid function (total T3, free T4 (FT4), & TSH within normal limits) at Week 26.

    Time frame: Week 26

Secondary outcomes

  1. Number of participants on BHV-1300 vs placebo who are not on an antithyroid drug and with normal thyroid hormone (Total T3 and FT4) at Week 26.

    Time frame: Week 26

  2. Change from baseline in TRAb (TBII) of participants on BHV-1300 vs placebo at Week 6

    Time frame: Baseline to Week 6

  3. Change from baseline in TRAb (TBII) of participants on BHV-1300 vs placebo at Week 26

    Time frame: Baseline to Week 26

  4. Exposure-adjusted Cumulative ATD dose, of participants on BHV-1300 vs placebo at Week 26

    Time frame: Week 26

  5. Time to normal thyroid hormones (defined as Total T3 & FT4 within normal limits) and off ATD of participants on BHV-1300 vs placebo

    Time frame: Up to 26 weeks

  6. Time to euthyroidism (defined as Total T3, FT4, and TSH within normal limits) and off ATD of participants on BHV-1300 vs placebo

    Time frame: Up to 26 weeks

  7. Change from baseline in Total IgG of participants on BHV-1300 vs placebo at Week 6

    Time frame: Baseline to Week 6

  8. Change from baseline in Total IgG of participants on BHV-1300 vs placebo at Week 26

    Time frame: Baseline to Week 26

  9. Number of participants who are TRAb seronegative (defined as TRAb < ULN) at Week 26

    Time frame: Week 26

  10. Number of participants who are euthyroid (defined as Total T3, FT4, and TSH within normal limits), off ATD and TRAb seronegative at Week 26

    Time frame: Week 26

  11. Number of unique participants with SAEs, moderate and severe AEs, AEs leading to discontinuation or deaths

    Time frame: Up to 26 weeks

  12. Number of unique participants with Grade 3 to 4 lab abnormalities

    Time frame: Up to 26 weeks

07

Study locations

63 of 63 sites recruiting
  • Site-044
    Tucson, Arizona 85741, United States
    Recruiting
  • Site-032
    Burbank, California 91501, United States
    Recruiting
  • Site-062
    Huntington Beach, California 92647, United States
    Recruiting
  • Site-056
    La Jolla, California 92037, United States
    Recruiting
  • Site-048
    Oakland, California 94611, United States
    Recruiting
  • Site-006
    San Diego, California 92108, United States
    Recruiting
  • Site-078
    South Gate, California 90280, United States
    Recruiting
  • Site-067
    Walnut Creek, California 94598, United States
    Recruiting
  • Site-035
    Washington D.C., District of Columbia 20010, United States
    Recruiting
  • Site-052
    Doral, Florida 33172, United States
    Recruiting
  • Site-066
    Fort Myers, Florida 33919, United States
    Recruiting
  • Site-019
    Hialeah, Florida 33016, United States
    Recruiting
  • Site-027
    Hollywood, Florida 33024, United States
    Recruiting
  • Site-061
    Miami, Florida 33010, United States
    Recruiting
  • Site-059
    Palm Beach Gardens, Florida 33410, United States
    Recruiting
  • Site-074
    Tampa, Florida 33634, United States
    Recruiting
  • Site-029
    Atlanta, Georgia 30303, United States
    Recruiting
  • Site-053
    Fayetteville, Georgia 30214, United States
    Recruiting
  • Site-031
    Champaign, Illinois 61822, United States
    Recruiting
  • Site-068
    Oak Brook, Illinois 60523, United States
    Recruiting
  • Site-080
    Springfield, Illinois 62702, United States
    Recruiting
  • Site-025
    Lenexa, Kansas 66234, United States
    Recruiting
  • Site-070
    Baton Rouge, Louisiana 70808, United States
    Recruiting
  • Site-046
    Farmington Hills, Michigan 48334, United States
    Recruiting
  • Site-004
    Kansas City, Missouri 64108, United States
    Recruiting
  • Site-015
    St Louis, Missouri 63110, United States
    Recruiting
  • Site-072
    Las Vegas, Nevada 89148, United States
    Recruiting
  • Site-047
    Albuquerque, New Mexico 87131, United States
    Recruiting
  • Site-077
    Orchard Park, New York 14224, United States
    Recruiting
  • Site-038
    Asheville, North Carolina 28803, United States
    Recruiting
  • Site-011
    Greenville, North Carolina 27834, United States
    Recruiting
  • Site-063
    Morehead City, North Carolina 28557, United States
    Recruiting
  • Site-064
    Morehead City, North Carolina 28557, United States
    Recruiting
  • Site-039
    Raleigh, North Carolina 27612, United States
    Recruiting
  • Site-033
    Statesville, North Carolina 28625, United States
    Recruiting
  • Site-045
    Wilmington, North Carolina 28405, United States
    Recruiting
  • Site-008
    Canton, Ohio 44718, United States
    Recruiting
  • Site-021
    Cincinnati, Ohio 45267, United States
    Recruiting
  • Site-037
    Norman, Oklahoma 73072, United States
    Recruiting
  • Site - 012
    Philadelphia, Pennsylvania 19107, United States
    Recruiting
  • Site-010
    North Charleston, South Carolina 29406, United States
    Recruiting
  • Site-016
    Chattanooga, Tennessee 37411, United States
    Recruiting
  • Site-017
    Memphis, Tennessee 38119, United States
    Recruiting
  • Site-081
    Amarillo, Texas 79124, United States
    Recruiting
  • Site-055
    Dallas, Texas 75231, United States
    Recruiting
  • Site-020
    Dallas, Texas 75246, United States
    Recruiting
  • Site-043
    Denton, Texas 76210, United States
    Recruiting
  • Site-042
    El Paso, Texas 79935, United States
    Recruiting
  • Site-034
    Houston, Texas 77040, United States
    Recruiting
  • Site-071
    Houston, Texas 77058, United States
    Recruiting
  • Site-054
    McKinney, Texas 75069, United States
    Recruiting
  • Site-057
    San Antonio, Texas 78251, United States
    Recruiting
  • Site-036
    Shavano Park, Texas 78231, United States
    Recruiting
  • Site-009
    Weslaco, Texas 78596, United States
    Recruiting
  • Site-013
    Layton, Utah 84041, United States
    Recruiting
  • Site-073
    Midlothian, Virginia 23112, United States
    Recruiting
  • Site-076
    Seattle, Washington 98104, United States
    Recruiting
  • Site-105
    Surrey, British Columbia V3T 4G8, Canada
    Recruiting
  • Site-100
    East York, Ontario M4G 3E8, Canada
    Recruiting
  • Site-101
    East York, Ontario M4G 3E8, Canada
    Recruiting
  • Site-103
    Winnipeg, MB R3C 0N2, Canada
    Recruiting
  • Site-060
    San Juan, 00909, Puerto Rico
    Recruiting
  • Site-058
    San Juan, 00926, Puerto Rico
    Recruiting
08

Timeline

5 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2026 (actual). Primary completion is estimated for Jan 2028, 19 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2026
First posted
Jun 22, 2026
StartActual
Jun 26, 2026
Primary completionEst.
Jan 2028
CompletionEst.
Feb 2028
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
13 sites added — first site in Canada
Show 13 added (8 United States, 4 Canada, 1 Puerto Rico)
  • Site-078 · South Gate, United States
  • Site-103 · Winnipeg, Canada
  • Site-035 · Washington D.C., United States
  • Site-077 · Orchard Park, United States
  • Site - 012 · Philadelphia, United States
  • Site-058 · San Juan, Puerto Rico
  • Site-056 · La Jolla, United States
  • Site-068 · Oak Brook, United States
  • Site-047 · Albuquerque, United States
  • Site-021 · Cincinnati, United States
  • Site-105 · Surrey, Canada
  • Site-100 · East York, Canada
  • Site-101 · East York, Canada
across 5 updates, Oct 1, 2026 – Nov 12, 2026
Show all 5 updates
  1. Nov 12, 2026
    7 sites added
    Show 7 added (4 United States, 3 Canada)
    • Site-056 · La Jolla, United States
    • Site-068 · Oak Brook, United States
    • Site-047 · Albuquerque, United States
    • Site-021 · Cincinnati, United States
    • Site-105 · Surrey, Canada
    • Site-100 · East York, Canada
    • Site-101 · East York, Canada
    + 1 other change: verification date
  2. Oct 19, 2026
    1 site added
    Show site
    • Site-058 · San Juan, Puerto Rico
  3. Oct 13, 2026
    2 sites added
    Show 2 added (2 United States)
    • Site-077 · Orchard Park, United States
    • Site - 012 · Philadelphia, United States
  4. Oct 6, 2026
    1 site added
    Show site
    • Site-035 · Washington D.C., United States
    + 1 other change: verification date
  5. Oct 1, 2026
    2 sites added — first site in Canada
    Show 2 added (1 United States, 1 Canada)
    • Site-078 · South Gate, United States
    • Site-103 · Winnipeg, Canada

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07661056
Lead sponsor
Biohaven Therapeutics Ltd.
Responsible party
Sponsor
First posted
Jun 22, 2026
Start date
Jun 26, 2026
Primary completion
Jan 2028 (estimated)
Completion
Feb 2028 (estimated)
Last update
Nov 12, 2026

Study contacts

Chief Medical Officer
Contact
clinicaltrials@biohavenpharma.com
203-404-0410

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BHV-1300

Start the discussion